• 1
    Van Damme L, Ramjee G, Alary M et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360: 9717.
  • 2
    Peterson L, Nanda K, Opoku BK et al. SAVVY [C31G] gel for prevention of HIv infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2: e1312.
  • 3
    Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359: 46372.
  • 4
    Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 197787.
  • 5
    McCormack S, Ramjee G, Kamali A et al. PRO2000 vaginal gel for prevention of HIV-1 infection [Microbicides Development Programme 301]: a phase 3, randomised, double-blind, parallel-group trial. Lancet 2010; 376: 132937.
  • 6
    Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 116874.
  • 7
    Miller CJ, Li Q, Abel K et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79: 921727.
  • 8
    Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62: 12739.
  • 9
    Terrazas-Aranda K, Van Herrewege Y, Hazuda D et al. Human immunodeficiency virus type 1 [HIV-1] integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother 2008; 52: 254454.
  • 10
    Tachet A, Dulioust E, Salmon D et al. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 1999; 13: 82331.
  • 11
    Sallé B, Brochard P, Bourry O et al. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis 2010; 202: 33744.
  • 12
    Kaizu M, Weiler AM, Weisgrau KL et al. Repeated intravaginal inoculation with cell-associated simian immunodeficiency virus results in persistent infection of nonhuman primates. J Infect Dis 2006; 194: 9126.
  • 13
    Keele BF, Giorgi EE, Salazar-Gonzalez JF et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 75527.
  • 14
    Salazar-Gonzalez JF, Salazar MG, Keele BF et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206: 127389.
  • 15
    Hladik F, Sakchalathorn P, Ballweber L et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type -1. Immunity 2007; 26: 25770.
  • 16
    Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8: 44757.
  • 17
    Keele BF, Estes JD. Barriers to mucosal transmission of immunodeficiency viruses. Blood 2011; 118: 83946.
  • 18
    Klasse PJ, Shattock RJ, Moore JP. Which topical microbicides for blocking HIV-1 transmission will work in the real world? PLoS Med 2006; 3: e351.
  • 19
    Si Z, Madani N, Cox JM et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004; 101: 503641.
  • 20
    Veazey RS, Shattock RJ, Pope M et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 3436.
  • 21
    Stiegler G, Armbruster C, Vcelar B et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in symptomatic HIV-1-infected humans: a phase I evaluation. AIDS 2002; 16: 201925.
  • 22
    Trkola A, Kuster H, Rusert P et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11: 5934.
  • 23
    Morris G, Chindrove S, Woodhall S, Wiggins R, Vcelar B, Lacey C. A prospective randomized double blind placebo-controlled phase 1 pharmacokinetic and safety study of a vaginal microbicide gel containing three potent broadly neutralizing antibodies [2F5, 2G12, 4E10] [MabGel]. Microbicides 2010 [Pittsburgh, PA], LB1, p. 229.
  • 24
    Forsman A, Beirnaert E, Aasa-Chapman MMI et al. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 [HIV-1]-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008; 82: 1206981.
  • 25
    Koh WWL, Steffensen S, Gonzalez-Pajuelo M et al. Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1. J Biol Chem 2010; 285: 1911624.
  • 26
    Martin L, Stricher F, Misse D et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 2003; 21: 716.
  • 27
    Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion. Nature 2005; 438: 99102.
  • 28
    He Y, Vassell R, Zaitseva M et al. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein intermediate at two sites. J Virol 2003; 77: 166671.
  • 29
    Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91: 97704.
  • 30
    Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2003; 2: 58793.
  • 31
    Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the ‘gatekeeper’ problem resolved? Nat Rev Microbiol 2006; 4: 3127.
  • 32
    Kuhmann SE, Hartley O. Targeting chemokine receptors in HIV; a status report. Annu Rev Pharmacol Toxicol 2008; 48: 42561.
  • 33
    De Clerq E. Strategies in the design of antiviral drugs. Nat Rev Drug Discov 2002; 1: 1325.
  • 34
    Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464: 21723.
  • 35
    Mehellou Y, De Clerq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 2010; 53: 52138.
  • 36
    Veazey RS, Ketas TJ, Dufour J et al. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010; 202: 73944.
  • 37
    Dragic T, Trkola A, Thompson DAD et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000; 97: 563944.
  • 38
    Maeda K, Das D, Hiromi O-A et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 2006; 281: 1268898.
  • 39
    Pastore C, Picchio GR, Galimi F et al. Two mechanisms for human immunodeficiency virus type1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 2003; 47: 50917.
  • 40
    Hartley O, Gaertner H, Wilken J et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA 2004; 101: 164605.
  • 41
    Arenzana-Seisdedos F, Virelizier J-L, Rousset D et al. HIV blocked by chemokine antagonist. Nature 1996; 383: 400.
  • 42
    Lederman M, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004; 306: 4857.
  • 43
    Gaertner G, Cerini F, Escola J-M et al. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low cost microbicide. Proc Natl Acad Sci USA 2008; 105: 1770611.
  • 44
    Veazey RS, Ling B, Green LC et al. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009; 199: 15257.
  • 45
    Cerini F, Landay A, Gichinga C et al. Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr 2008; 49: 4726.
  • 46
    Cranage M, Sharpe S, Herrera C et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008; 5: e157.
  • 47
    Parikh UM, Dobard C, Sharma S et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009; 83: 1035865.
  • 48
    Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res 2008; 134: 14756.
  • 49
    Kenney J, Aravantinou M, Singer R et al. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2009; 4: e8060.
  • 50
    Caron M, Besson G, Etenna SL-D et al. Protective properties of non-nucleoside reverse transcriptase inhibitor [MC1220] incorporated into liposome against intravaginal challenge of rhesus macaques with RT-SHIV. Virology 2010; 405: 22533.
  • 51
    Fletcher P, Harman S, Azijn H et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009; 53: 48795.
  • 52
    Nuttall JP, Thake DC, Lewis MG, Ferkany JW, Romano JW, Mitchnick MA. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob Agents Chemother 2008; 52: 90914.
  • 53
    Romano J, Variano B, Coplan P et al. Safety and availability of dapivirine [TMC120] delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25: 4838.
  • 54
    Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg R. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 41623.
  • 55
    Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991; 67: 121121.
  • 56
    Dobard C, Sharma S, Parikh U et al . High protection against vaginal infection in macaques by PEP with gel containing RAL. 18 th Conference on retroviruses and opportunistic infections 2011; Paper 30.
  • 57
    Vandegraff N, Engelman A. Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev Mol Med 2007; 9: 119. DOI: 10.1017/S1462399407000257.
  • 58
    De Luca L, Ferro S, Gitto R et al. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem 2010; 18: 751521.
  • 59
    Ganser-Pornillos BK, Yeager M, Sundquistet WI. The structural biology of HIV assembly. Curr Opin Struct Biol 2008; 18: 20317.
  • 60
    Bierman WFW, van Agtmael MA, Nijhuis N, Danner SA, Boucher CAB. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23: 27991.
  • 61
    Arribas JR, Pulido F, Delgado R et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression. J Acquir Immune Defic Syndr 2005; 40: 2807.
  • 62
    Coggins C, Blanchard K, Alvarez F et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect 2000; 76: 4803.
  • 63
    Joglekar N, Joshi S, Kakde M et al. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India. AIDS Care 2007; 19: 81721.
  • 64
    Ventuneac A, Carballo-Dieguez A, McGowan I et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav 2010; 14: 61828.
  • 65
    Morris GC, Lacey CJN. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr Opin Infect Dis 2010; 23: 5763.
  • 66
    Turner AN, De Kock AE, Meehan-Ritter A et al. Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol 2009; 62: 75965.
  • 67
    Malcolm RK, Edwards K-L, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res 2010; 88S: S309.
  • 68
    Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD. Long-term release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56: 9546.
  • 69
    Woolfson AD, Malcolm RK, Morrow RJ. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC120 as an HIV microbicide. Int J Pharm 2006; 325: 829.
  • 70
    Garg S, Goldman D, Krumme K, Rohan LC, Smoot S, Friend DR. Advances in development, scale-up and manufacturing of microbicide gels. Antiviral Res 2010; 88S: S1929.
  • 71
    Lis O, Robillard K, Chan GNY, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2009; 31: 2235.
  • 72
    Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M et al. Cell entry and export of nucleoside analogues. Virus Res 2005; 107: 15164.
  • 73
    Bourdet DL, Pollack GM, Thakker DR. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in caco-2 cells. Pharm Res 2006; 23: 117887.
  • 74
    Englund G, Rorsman F, Rönnblom A et al. Regional levels of drug transporters along the human intestinal tract; co-expression of ABC and SLC transporters and comparison with caco-2 cells. Eur J Pharm Sci 2006; 29: 26977.
  • 75
    Finstad CL, Saigo PE, Rubin SC et al. Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions. J Histochem Cytochem 1990; 38: 167781.
  • 76
    Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 2009; 296: C57082.
  • 77
    Lucia MB, Rutella S, Leone G, Vella S, Cauda R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 2001; 27: 32130.
  • 78
    König SK, Herzog M, Theile D, Zembruski N, Haefeli WE, Weiss J. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010; 65: 231928.
  • 79
    Zastre JA, Chan GNY, Ronaldson PT et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neuro Res 2009; 87: 102336.
  • 80
    Consensus Statement by IPM and the Executive Committee of the IPM Scientific Advisory Board. 2008. The use of antiretroviral drugs [ARVs] in microbicides and the potential for the development of drug-resistant strains of HIV. .
  • 81
    Fetherston S, Malcolm K, Woolfson D, Lacey C, Shattock R. Formulation development of matrix-type silicone elastomer vaginal rings containing protease inhibitors. Microbicides 2010 [Pittsbirgh, PA], Paper 184.
  • 82
    Loxley A, Gokhale A, McConnell J, Okoh O, Edwards KL, Mitchnick M. Combination ethylene vinyl acetate intravaginal rings containing dapivirine and maraviroc. Microbicides 2010 [Pittsbirgh, PA], Paper 185.
  • 83
    Akil A, Dezzutti C, Moncla B et al. Quick-dissolve films as drug delivery systems for combination microbicides. Microbicides 2010 [Pittsbirgh, PA], Paper 231.
  • 84
    Garg S, Gupta J, Othmana A, Singh S. Design of novel solid vaginal dosage form of dapivirine NNRTI and BMS-599793 [DS003] entry inhibitor in combination. Microbicides 2010 [Pittsbirgh, PA], Paper 181.
  • 85
    Padian NS, van der Straten A, Ramjee G et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370: 25161.
  • 86
    Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339: 50410.